The Cost-Effectiveness of Bendamustine Versus Fludarabine for the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Mexico.

MLA

Bertwistle, D., et al. “The Cost-Effectiveness of Bendamustine Versus Fludarabine for the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Mexico.” Value in Health, vol. 16, no. 7, Nov. 2013, p. A409. EBSCOhost, https://doi.org/10.1016/j.jval.2013.08.497.

APA

Bertwistle, D., Munakata, J., Wehler, E., Leyva, V., Valencia, A., Hernandez, A., de la Torre, L., & Gonzalez, L. (2013). The Cost-Effectiveness of Bendamustine Versus Fludarabine for the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Mexico. Value in Health, 16(7), A409. https://doi.org/10.1016/j.jval.2013.08.497

Chicago

Bertwistle, D., J. Munakata, E. Wehler, V. Leyva, A. Valencia, A. Hernandez, L. de la Torre, and L. Gonzalez. 2013. “The Cost-Effectiveness of Bendamustine Versus Fludarabine for the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Mexico.” Value in Health 16 (7): A409. doi:10.1016/j.jval.2013.08.497.